Chapter 7Assessment of factors relevant to the NHS and other parties

The potential extra cost to the NHS of providing adalimumab, etanercept or ustekinumab to children and young people with moderate to severe plaque psoriasis is largely uncertain, given the paucity of evidence on the health-care resource use specific to this population and the uncertainties in the effectiveness evidence base. The resource use associated with BSC in terms of the expected number of hospitalisations per annum was identified as a key area of uncertainty, as in previous TAs of psoriasis in adults. Reducing uncertainty at this level would allow a more accurate assessment of the potential impact on the consumption of NHS resources of providing biological treatment to children and young people with moderate to severe plaque psoriasis.